欢迎来到天天文库
浏览记录
ID:33211332
大小:5.52 MB
页数:58页
时间:2019-02-22
《核不均一核糖核蛋白l在人肾透明细胞癌组织中表达与其临床意义-(5937)》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、万方数据硕士学位论文82.0%(50/61)和48.3%(14/29),组间比较差异有显著性∽2、。HnRNPL阳性组患者5年生存率75.0%(舛%C/,64.024%,85.976%),然而hnRNPL阴性患者的5年生存率仅有20.8%(95%C1,4.532%,37.068%);对肿瘤体积小于178cm3的患者生存时间数据分析显示在小体积肾癌中hnRNPL的差异表达患者生存时间也会产生显著差异(P3、07):临床分期I的患者差异也较为显著(尸4、白在人肾透明细胞癌中的表达水平显著低于癌旁非肿瘤组织,且与肾透明细胞癌病理参数呈负相关,其表达水平的下降提示患者更差的预后;(2)HnRNPL可能作为肾透明细胞癌患者预后的独立危险因素;(3)HnRNPL与肾透明细胞癌发生存在联系,其可能作为肾透明细胞癌患者早期诊断和预后评估的分子标志物。V万方数据摘要(4)HnRNPL可能通过与lncRNA的相互作用参与肾透明细胞癌的发生。关键词:肾透明细胞癌;hnRNPL:免疫组织化学;Westemblot;LncRNAVI万方数据硕士学位论文Expressiono5、fhnRNPLproteininhumanclearcellrenalcellcarcinomatissuesanditsclinicalsignificanceName:FangpengShuSupervisor:Assoc.Prof.XiangmingMaoABSTRACTBackgroundandobjectiveRenalCellCarcinoma(kidney),whichisoriginatedfrommalignanttumouroftheurinarytubularepithelialc6、ellsofRenalparenchyma,ishighgradetumorinurinarysystem,alsoisoneofthemostcommontumor,alsocalledRenaladenocarcinoma,accountingfor85%oftheprimarytumorkidney-90%,ofwhich80%-90%ofClearCellCarcinoma(ClearCelltakesCellCarcinoma),anditsincidenceisrisinginrecenty7、ears.Duetothepathogenesisofrenalclearcellcarcinomaisunclear,theearlyclinicalmanifestationisnottypical,ottenfoundinnearlyhalfofthepatientshadend-stagekidneyordistantmetastasis,andlossofopportunityofoperation.Kidneycancerisnotsensitivetoradiotherapyandchem8、otherapyareatthesametime;Efficacyofimmunotherapyislimited,therefore,itsmostmaintreatmentissurgicalresection,butthepostoperativerecurrencerateof25%-50%.Ingeneral,drugsandsurgeryforrenalcellcarcinomapatientsprogression-frees
2、。HnRNPL阳性组患者5年生存率75.0%(舛%C/,64.024%,85.976%),然而hnRNPL阴性患者的5年生存率仅有20.8%(95%C1,4.532%,37.068%);对肿瘤体积小于178cm3的患者生存时间数据分析显示在小体积肾癌中hnRNPL的差异表达患者生存时间也会产生显著差异(P3、07):临床分期I的患者差异也较为显著(尸4、白在人肾透明细胞癌中的表达水平显著低于癌旁非肿瘤组织,且与肾透明细胞癌病理参数呈负相关,其表达水平的下降提示患者更差的预后;(2)HnRNPL可能作为肾透明细胞癌患者预后的独立危险因素;(3)HnRNPL与肾透明细胞癌发生存在联系,其可能作为肾透明细胞癌患者早期诊断和预后评估的分子标志物。V万方数据摘要(4)HnRNPL可能通过与lncRNA的相互作用参与肾透明细胞癌的发生。关键词:肾透明细胞癌;hnRNPL:免疫组织化学;Westemblot;LncRNAVI万方数据硕士学位论文Expressiono5、fhnRNPLproteininhumanclearcellrenalcellcarcinomatissuesanditsclinicalsignificanceName:FangpengShuSupervisor:Assoc.Prof.XiangmingMaoABSTRACTBackgroundandobjectiveRenalCellCarcinoma(kidney),whichisoriginatedfrommalignanttumouroftheurinarytubularepithelialc6、ellsofRenalparenchyma,ishighgradetumorinurinarysystem,alsoisoneofthemostcommontumor,alsocalledRenaladenocarcinoma,accountingfor85%oftheprimarytumorkidney-90%,ofwhich80%-90%ofClearCellCarcinoma(ClearCelltakesCellCarcinoma),anditsincidenceisrisinginrecenty7、ears.Duetothepathogenesisofrenalclearcellcarcinomaisunclear,theearlyclinicalmanifestationisnottypical,ottenfoundinnearlyhalfofthepatientshadend-stagekidneyordistantmetastasis,andlossofopportunityofoperation.Kidneycancerisnotsensitivetoradiotherapyandchem8、otherapyareatthesametime;Efficacyofimmunotherapyislimited,therefore,itsmostmaintreatmentissurgicalresection,butthepostoperativerecurrencerateof25%-50%.Ingeneral,drugsandsurgeryforrenalcellcarcinomapatientsprogression-frees
3、07):临床分期I的患者差异也较为显著(尸4、白在人肾透明细胞癌中的表达水平显著低于癌旁非肿瘤组织,且与肾透明细胞癌病理参数呈负相关,其表达水平的下降提示患者更差的预后;(2)HnRNPL可能作为肾透明细胞癌患者预后的独立危险因素;(3)HnRNPL与肾透明细胞癌发生存在联系,其可能作为肾透明细胞癌患者早期诊断和预后评估的分子标志物。V万方数据摘要(4)HnRNPL可能通过与lncRNA的相互作用参与肾透明细胞癌的发生。关键词:肾透明细胞癌;hnRNPL:免疫组织化学;Westemblot;LncRNAVI万方数据硕士学位论文Expressiono5、fhnRNPLproteininhumanclearcellrenalcellcarcinomatissuesanditsclinicalsignificanceName:FangpengShuSupervisor:Assoc.Prof.XiangmingMaoABSTRACTBackgroundandobjectiveRenalCellCarcinoma(kidney),whichisoriginatedfrommalignanttumouroftheurinarytubularepithelialc6、ellsofRenalparenchyma,ishighgradetumorinurinarysystem,alsoisoneofthemostcommontumor,alsocalledRenaladenocarcinoma,accountingfor85%oftheprimarytumorkidney-90%,ofwhich80%-90%ofClearCellCarcinoma(ClearCelltakesCellCarcinoma),anditsincidenceisrisinginrecenty7、ears.Duetothepathogenesisofrenalclearcellcarcinomaisunclear,theearlyclinicalmanifestationisnottypical,ottenfoundinnearlyhalfofthepatientshadend-stagekidneyordistantmetastasis,andlossofopportunityofoperation.Kidneycancerisnotsensitivetoradiotherapyandchem8、otherapyareatthesametime;Efficacyofimmunotherapyislimited,therefore,itsmostmaintreatmentissurgicalresection,butthepostoperativerecurrencerateof25%-50%.Ingeneral,drugsandsurgeryforrenalcellcarcinomapatientsprogression-frees
4、白在人肾透明细胞癌中的表达水平显著低于癌旁非肿瘤组织,且与肾透明细胞癌病理参数呈负相关,其表达水平的下降提示患者更差的预后;(2)HnRNPL可能作为肾透明细胞癌患者预后的独立危险因素;(3)HnRNPL与肾透明细胞癌发生存在联系,其可能作为肾透明细胞癌患者早期诊断和预后评估的分子标志物。V万方数据摘要(4)HnRNPL可能通过与lncRNA的相互作用参与肾透明细胞癌的发生。关键词:肾透明细胞癌;hnRNPL:免疫组织化学;Westemblot;LncRNAVI万方数据硕士学位论文Expressiono
5、fhnRNPLproteininhumanclearcellrenalcellcarcinomatissuesanditsclinicalsignificanceName:FangpengShuSupervisor:Assoc.Prof.XiangmingMaoABSTRACTBackgroundandobjectiveRenalCellCarcinoma(kidney),whichisoriginatedfrommalignanttumouroftheurinarytubularepithelialc
6、ellsofRenalparenchyma,ishighgradetumorinurinarysystem,alsoisoneofthemostcommontumor,alsocalledRenaladenocarcinoma,accountingfor85%oftheprimarytumorkidney-90%,ofwhich80%-90%ofClearCellCarcinoma(ClearCelltakesCellCarcinoma),anditsincidenceisrisinginrecenty
7、ears.Duetothepathogenesisofrenalclearcellcarcinomaisunclear,theearlyclinicalmanifestationisnottypical,ottenfoundinnearlyhalfofthepatientshadend-stagekidneyordistantmetastasis,andlossofopportunityofoperation.Kidneycancerisnotsensitivetoradiotherapyandchem
8、otherapyareatthesametime;Efficacyofimmunotherapyislimited,therefore,itsmostmaintreatmentissurgicalresection,butthepostoperativerecurrencerateof25%-50%.Ingeneral,drugsandsurgeryforrenalcellcarcinomapatientsprogression-frees
此文档下载收益归作者所有